Surgical Endoscopy

, Volume 25, Issue 8, pp 2650–2659 | Cite as

Early effects of gastric bypass on endothelial function, inflammation, and cardiovascular risk in obese patients

  • Stacy A. Brethauer
  • Helen M. Heneghan
  • Shai Eldar
  • Patrick Gatmaitan
  • Hazel Huang
  • Sangeeta Kashyap
  • Heather L. Gornik
  • John P. Kirwan
  • Philip R. Schauer



Obesity is associated with a chronic low-grade inflammatory state, insulin resistance, and endothelial dysfunction, all of which contribute to increased risk of cardiovascular disease. We hypothesized that gastric bypass would produce rapid improvements in endothelial function, reduce inflammation, and lead to a decrease in cardiovascular risk.


We performed a prospective study of morbidly obese patients who underwent laparoscopic Roux-en-Y gastric bypass (RYGB). Clinical data, biochemical markers of inflammation, and parameters indicative of cardiovascular risk were collected preoperatively and at 3 and 6 months postoperatively. Metabolic and inflammatory mediators that were quantified included C-reactive protein, fibrinogen, PAI-1, IL-6, IL-10, IL-1Ra, adiponectin, leptin, triglycerides, total cholesterol, HDL, LDL, glucose, insulin, and HbA1c. Brachial artery reactivity testing (BART) was performed to assess peripheral arterial endothelial function, and Framingham cardiovascular risk score (FRS) was calculated on all study participants pre- and postoperatively.


Fifteen patients (11 female) were enrolled (age = 49.2 ± 10.4 years; BMI = 48.1 ± 5.3 kg/m2). Six months post RYGB, mean BMI decreased to 35.4 ± 4.5, corresponding to 51.7% excess weight loss (P < 0.001). Mean waist circumference decreased significantly from 132 cm at baseline to 110 cm at 3 months (P = 0.003) and 107 cm at 6 months (P < 0.001). Six months after RYGB, weight loss led to significant improvements in clinical parameters indicative of cardiovascular disease or risk, including brachial artery diameter, endothelial independent vasodilation, and FRS. Favorable improvements in the proinflammatory markers CRP (P = 0.01) and leptin (P = 0.005), the anti-inflammatory mediator adiponectin (P = 0.002), and insulin sensitivity (HOMA-IR, P = 0.007) were evident at 3 months. At 6 months, improvements in CRP, leptin, and fasting insulin were maintained and fibrinogen levels also decreased (P = 0.047). Adiponectin continued to increase at 6 months (P = 0.004).


Gastric bypass is associated with early reversal of endothelial dysfunction, a more favorable inflammatory milieu, and, most importantly, a reduction in cardiovascular risk.


Gastric bypass Inflammation Cardiovascular BART Endothelial 


  1. 1.
    Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999–2008. JAMA 303(3):235–241PubMedCrossRefGoogle Scholar
  2. 2.
    Brown I, Thompson J, Tod A, Jones G (2006) Primary care support for tackling obesity: a qualitative study of the perceptions of obese patients. Br J Gen Pract 56(530):666–672PubMedGoogle Scholar
  3. 3.
    Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, Rimm E, Colditz GA (2001) Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 161(13):1581–1586PubMedCrossRefGoogle Scholar
  4. 4.
    Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH (1999) The disease burden associated with overweight and obesity. JAMA 282(16):1523–1529PubMedCrossRefGoogle Scholar
  5. 5.
    Finkelstein EA, Brown DS, Wrage LA, Allaire BT, Hoerger TJ (2010) Individual and aggregate years-of-life-lost associated with overweight and obesity. Obesity (Silver Spring) 18(2):333–339CrossRefGoogle Scholar
  6. 6.
    Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB (2003) Years of life lost due to obesity. JAMA 289(2):187–193PubMedCrossRefGoogle Scholar
  7. 7.
    Calabro P, Golia E, Maddaloni V, Malvezzi M, Casillo B, Marotta C, Calabro R, Golino P (2009) Adipose tissue-mediated inflammation: the missing link between obesity and cardiovascular disease? Intern Emerg Med 4(1):25–34PubMedCrossRefGoogle Scholar
  8. 8.
    O’Brien PE, Dixon JB, Laurie C, Anderson M (2005) A prospective randomized trial of placement of the laparoscopic adjustable gastric band: comparison of the perigastric and pars flaccida pathways. Obes Surg 15(6):820–826PubMedCrossRefGoogle Scholar
  9. 9.
    Samuel VT, Petersen KF, Shulman GI (2010) Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375(9733):2267–2277PubMedCrossRefGoogle Scholar
  10. 10.
    Bjorntorp P (1993) Visceral obesity: a “civilization syndrome”. Obes Res 1(3):206–222PubMedGoogle Scholar
  11. 11.
    Brunzell JD, Hokanson JE (1999) Dyslipidemia of central obesity and insulin resistance. Diabetes Care 22(Suppl 3):C10–C13PubMedGoogle Scholar
  12. 12.
    Tretjakovs P, Jurka A, Bormane I, Mackevics V, Mikelsone I, Balode L, Reihmane D, Stukena I, Bahs G, Aivars JI, Pirags V (2009) Relation of inflammatory chemokines to insulin resistance and hypoadiponectinemia in coronary artery disease patients. Eur J Intern Med 20(7):712–717PubMedCrossRefGoogle Scholar
  13. 13.
    Vazquez LA, Pazos F, Berrazueta JR, Fernandez-Escalante C, Garcia-Unzueta MT, Freijanes J, Amado JA (2005) Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab 90(1):316–322PubMedCrossRefGoogle Scholar
  14. 14.
    Shoelson SE, Herrero L, Naaz A (2007) Obesity, inflammation, and insulin resistance. Gastroenterology 132(6):2169–2180PubMedCrossRefGoogle Scholar
  15. 15.
    Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15(7):539–553PubMedCrossRefGoogle Scholar
  16. 16.
    Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET (2002) Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 105(5):564–569PubMedCrossRefGoogle Scholar
  17. 17.
    Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB (1999) Elevated C-reactive protein levels in overweight and obese adults. JAMA 282(22):2131–2135PubMedCrossRefGoogle Scholar
  18. 18.
    Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336(14):973–979PubMedCrossRefGoogle Scholar
  19. 19.
    Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1998) Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97(5):425–428PubMedGoogle Scholar
  20. 20.
    Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB (1999) C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends, Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99(2):237–242PubMedGoogle Scholar
  21. 21.
    Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98(8):731–733PubMedGoogle Scholar
  22. 22.
    Bluher M, Fasshauer M, Tonjes A, Kratzsch J, Schon MR, Paschke R (2005) Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism. Exp Clin Endocrinol Diabetes 113(9):534–537PubMedCrossRefGoogle Scholar
  23. 23.
    Manigrasso MR, Ferroni P, Santilli F, Taraborelli T, Guagnano MT, Michetti N, Davi G (2005) Association between circulating adiponectin and interleukin-10 levels in android obesity: effects of weight loss. J Clin Endocrinol Metab 90(10):5876–5879PubMedCrossRefGoogle Scholar
  24. 24.
    Pickup JC, Mattock MB, Chusney GD, Burt D (1997) NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40(11):1286–1292PubMedCrossRefGoogle Scholar
  25. 25.
    Syed MA, Barinas-Mitchell E, Pietropaolo SL, Zhang YJ, Henderson TS, Kelley DE, Korytkowski MT, Donahue RP, Tracy RP, Trucco M, Kuller LH, Pietropaolo M (2002) Is type 2 diabetes a chronic inflammatory/autoimmune disease? Diabetes Nutr Metab 15(2):68–83PubMedGoogle Scholar
  26. 26.
    Heilbronn LK, Noakes M, Clifton PM (2001) Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol 21(6):968–970PubMedCrossRefGoogle Scholar
  27. 27.
    Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M, D’Andrea F, Molinari AM, Giugliano D (2002) Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 105(7):804–809PubMedCrossRefGoogle Scholar
  28. 28.
    Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B (2000) Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 85(9):3338–3342PubMedCrossRefGoogle Scholar
  29. 29.
    Monzillo LU, Hamdy O, Horton ES, Ledbury S, Mullooly C, Jarema C, Porter S, Ovalle K, Moussa A, Mantzoros CS (2003) Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance. Obes Res 11(9):1048–1054PubMedCrossRefGoogle Scholar
  30. 30.
    Laimer M, Ebenbichler CF, Kaser S, Sandhofer A, Weiss H, Nehoda H, Aigner F, Patsch JR (2002) Markers of chronic inflammation and obesity: a prospective study on the reversibility of this association in middle-aged women undergoing weight loss by surgical intervention. Int J Obes Relat Metab Disord 26(5):659–662PubMedCrossRefGoogle Scholar
  31. 31.
    Williams IL et al (2005) Endothelial function and weight loss in obese humans. Obes Surg 15(7):1055–1060PubMedCrossRefGoogle Scholar
  32. 32.
    NIH conference (1991) Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med 115(12):956-961Google Scholar
  33. 33.
    Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340(8828):1111–1115PubMedCrossRefGoogle Scholar
  34. 34.
    Kuvin JT, Patel AR, Sliney KA, Pandian NG, Rand WM, Udelson JE, Karas RH (2001) Peripheral vascular endothelial function testing as a noninvasive indicator of coronary artery disease. J Am Coll Cardiol 38(7):1843–1849PubMedCrossRefGoogle Scholar
  35. 35.
    Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R (2002) Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39(2):257–265PubMedCrossRefGoogle Scholar
  36. 36.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419PubMedCrossRefGoogle Scholar
  37. 37.
    Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97(18):1837–1847PubMedGoogle Scholar
  38. 38.
    Peretz A, Leotta DF, Sullivan JH, Trenga CA, Sands FN, Aulet MR, Paun M, Gill EA, Kaufman JD (2007) Flow mediated dilation of the brachial artery: an investigation of methods requiring further standardization. BMC Cardiovasc Disord 7:11PubMedCrossRefGoogle Scholar
  39. 39.
    Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, Lieberman EH, Ganz P, Creager MA, Yeung AC et al (1995) Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 26(5):1235–1241PubMedCrossRefGoogle Scholar
  40. 40.
    Rossi R, Nuzzo A, Origliani G, Modena MG (2008) Prognostic role of flow-mediated dilation and cardiac risk factors in post-menopausal women. J Am Coll Cardiol 51(10):997–1002PubMedCrossRefGoogle Scholar
  41. 41.
    Takase B, Uehata A, Akima T, Nagai T, Nishioka T, Hamabe A, Satomura K, Ohsuzu F, Kurita A (1998) Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol 82(12):1535-1539, A7-A8Google Scholar
  42. 42.
    Gokce N et al (2005) Effect of medical and surgical weight loss on endothelial vasomotor function in obese patients. Am J Cardiol 95(2):266–268PubMedCrossRefGoogle Scholar
  43. 43.
    Demerath EW, Reed D, Rogers N, Sun SS, Lee M, Choh AC, Couch W, Czerwinski SA, Chumlea WC, Siervogel RM, Towne B (2008) Visceral adiposity and its anatomical distribution as predictors of the metabolic syndrome and cardiometabolic risk factor levels. Am J Clin Nutr 88(5):1263–1271PubMedGoogle Scholar
  44. 44.
    Wajchenberg BL, Giannella-Neto D, da Silva ME, Santos RF (2002) Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. Horm Metab Res 34(11–12):616–621PubMedCrossRefGoogle Scholar
  45. 45.
    Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T (1989) The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 169(1):333–338PubMedCrossRefGoogle Scholar
  46. 46.
    Meier-Ewert HK, Ridker PM, Rifai N, Price N, Dinges DF, Mullington JM (2001) Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 47(3):426–430PubMedGoogle Scholar
  47. 47.
    Tan KC, Chow WS, Tam S, Bucala R, Betteridge J (2004) Association between acute-phase reactants and advanced glycation end products in type 2 diabetes. Diabetes Care 27(1):223–228PubMedCrossRefGoogle Scholar
  48. 48.
    Linscheid P, Christ-Crain M, Stoeckli R, Reusch CE, Lutz TA, Muller B, Keller U (2008) Increase in high molecular weight adiponectin by bariatric surgery-induced weight loss. Diabetes Obes Metab 10(12):1266–1270PubMedGoogle Scholar
  49. 49.
    Trakhtenbroit MA, Leichman JG, Algahim MF, Miller CC III, Moody FG, Lux TR, Taegtmeyer H (2009) Body weight, insulin resistance, and serum adipokine levels 2 years after 2 types of bariatric surgery. Am J Med 122(5):435–442PubMedCrossRefGoogle Scholar
  50. 50.
    Kligman MD, Dexter DJ, Omer S, Park AE (2008) Shrinking cardiovascular risk through bariatric surgery: application of Framingham risk score in gastric bypass. Surgery 143(4):533–538PubMedCrossRefGoogle Scholar
  51. 51.
    Torquati A, Wright K, Melvin W, Richards W (2007) Effect of gastric bypass operation on Framingham and actual risk of cardiovascular events in class II to III obesity. J Am Coll Surg 204(5):776–782 (discussion 773–782)PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Stacy A. Brethauer
    • 1
  • Helen M. Heneghan
    • 1
  • Shai Eldar
    • 1
  • Patrick Gatmaitan
    • 1
  • Hazel Huang
    • 2
  • Sangeeta Kashyap
    • 3
  • Heather L. Gornik
    • 4
  • John P. Kirwan
    • 2
  • Philip R. Schauer
    • 1
  1. 1.Bariatric and Metabolic Institute, M61, Cleveland ClinicClevelandUSA
  2. 2.Department of PathobiologyLerner Research Institute, Cleveland ClinicClevelandUSA
  3. 3.Endocrinology and Metabolism InstituteClevelandUSA
  4. 4.Heart and Vascular InstituteClevelandUSA

Personalised recommendations